Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. announced that a U.S. District Court entered a Final Judgment in its patent case against Alcon, awarding the company $55.4 million in total monetary damages and confirming that the asserted patent claims are valid and were willfully infringed.
The award includes $34.0 million in past damages through April 26, 2024, $14.7 million in supplemental damages through March 31, 2026, and $6.8 million in pre‑judgment and post‑judgment interest through April 17, 2026. The judgment also grants an ongoing 10% royalty on Hydrus Microstent revenue until the last of the patents expires. However, Alcon may appeal, and Sight Sciences will not receive any monetary damages unless appeals conclude or the appeal period ends without appeal, and certain patent reexamination outcomes could affect its ability to collect.
Sight Sciences, Inc. is holding a completely virtual 2026 Annual Meeting of Stockholders on June 4, 2026 at 9:00 a.m. Pacific Time to elect two Class II directors and seek ratification of Deloitte & Touche LLP as independent auditor.
Stockholders of record as of April 8, 2026, when 54,403,542 shares of common stock were outstanding and entitled to vote, may attend and vote online using a 16-digit control number. The proxy statement also details board composition, committee structures, executive officer biographies, and the company’s executive compensation philosophy.
Deloitte & Touche LLP, which has audited the company since 2019, billed audit-related fees totaling $1,461,395 for 2025. The Audit Committee recommends including the 2025 audited financial statements in the Form 10‑K and asks stockholders to ratify Deloitte’s continued engagement for 2026.
Sight Sciences, Inc. Chief Financial Officer James Rodberg reported an open-market sale of 7,231 shares of common stock on April 6, 2026 at a weighted average price of $3.55 per share. According to the disclosure, the shares were sold to cover his tax liability tied to recently vesting restricted stock units.
Following this tax-related sale, Rodberg directly holds a total of 230,939 shares of common stock, including 47,160 currently held shares and 183,779 additional shares that will be acquired upon future vesting and settlement of restricted stock units. The transaction represents a small portion of his overall equity position.
Sight Sciences, Inc. Chief Legal Officer Jeremy B. Hayden sold 13,761 shares of common stock on April 6, 2026 at a weighted average price of $3.55 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this tax-related sale, he held a total of 369,770 shares, including 87,274 shares of common stock and 282,496 additional shares that will be received upon future vesting and settlement of RSUs.
Sight Sciences, Inc. Schedule 13G/A amendment shows KCK Ltd. and Nael Karim Kassar beneficially own 1,438,094 shares of Common Stock, representing 2.7% of the class based on 54,005,984 shares outstanding as of February 26, 2026. The filing reports shared voting and dispositive power over these shares and is signed by the filer and Sight Sciences' CEO.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported an open-market sale of 25,874 shares of common stock at a weighted average price of $3.48 per share. According to the filing, these shares were sold to cover her tax liability arising from the vesting of restricted stock units.
After this transaction, Bauerlein holds 701,621 shares of common stock, including 156,788 shares currently held and 544,833 shares that will be acquired upon the future vesting and settlement of unvested restricted stock units.
Sight Sciences, Inc. director and Chief Technology Officer David Badawi reported an open-market sale of 8,168 shares of Common Stock at a weighted average price of $3.48 per share. According to the footnotes, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi's reported holdings total 1,990,290 shares, consisting of 1,804,359 shares of common stock and 185,931 shares that will be acquired upon future vesting and settlement of restricted stock units. The sale represents a small portion of his overall position.
Sight Sciences EVP Taylor Brenton sold 2,869 shares of Common Stock at a weighted average price of $3.70 per share. According to the disclosure, these shares were sold solely to cover tax liabilities arising from the vesting of restricted stock units, rather than as a discretionary portfolio move.
After this tax-related sale, Brenton holds 267,807 shares, including 31,631 shares of Common Stock and 236,176 additional shares that are scheduled to be received upon future vesting and settlement of RSUs. This indicates the transaction affected only a small portion of his overall equity exposure to the company.